Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder

Conclusions Mirabegron, a novel first-in-class therapy, appeared as a safe and effective alternative for children with idiopathic OAB refractory to antimuscarinics. Patient summary We evaluated the efficacy and safety of mirabegron to treat incontinence in pediatric patients. Continence, median voided volumes, and quality of life were improved after the introduction of mirabegron, and few side effects were reported. Mirabegron, a β3-adrenoreceptor agonist, is of interest for the treatment of overactive bladder in pediatrics because it improves median voided volume, quality of life, and number of incontinence episodes. Few side effects are reported.
Source: European Urology - Category: Urology & Nephrology Source Type: research